Kim ES, Kang B. Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease. World J Gastroenterol 2023; 29(18): 2784-2797 [PMID: 37274072 DOI: 10.3748/wjg.v29.i18.2784]
Please LOGIN to submit a new comment.